Concepts (53)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 1 | 2004 | 316 | 0.190 |
Why?
|
| Lung Neoplasms | 2 | 2004 | 625 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 2 | 2005 | 260 | 0.110 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2008 | 27 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2008 | 53 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2008 | 142 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 189 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2005 | 290 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2005 | 42 | 0.060 |
Why?
|
| Lymphomatoid Granulomatosis | 1 | 2003 | 3 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 145 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2003 | 62 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2004 | 89 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 175 | 0.050 |
Why?
|
| Apoptosis | 1 | 2004 | 251 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 124 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 324 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 218 | 0.050 |
Why?
|
| Vincristine | 2 | 2005 | 26 | 0.030 |
Why?
|
| Doxorubicin | 2 | 2005 | 45 | 0.030 |
Why?
|
| Cyclophosphamide | 2 | 2005 | 55 | 0.030 |
Why?
|
| Rituximab | 2 | 2005 | 53 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2005 | 38 | 0.030 |
Why?
|
| Prednisone | 2 | 2005 | 67 | 0.030 |
Why?
|
| Humans | 4 | 2008 | 29337 | 0.020 |
Why?
|
| Ampulla of Vater | 1 | 2008 | 6 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2008 | 31 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 26 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2008 | 62 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 75 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2008 | 127 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2008 | 135 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2008 | 3478 | 0.020 |
Why?
|
| Twins, Dizygotic | 1 | 2005 | 4 | 0.020 |
Why?
|
| Male | 3 | 2008 | 15621 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 223 | 0.020 |
Why?
|
| Antigens, CD20 | 1 | 2003 | 5 | 0.020 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2003 | 9 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2003 | 13 | 0.020 |
Why?
|
| Recurrence | 1 | 2005 | 350 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 2003 | 12 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 37 | 0.010 |
Why?
|
| Vision Disorders | 1 | 2003 | 23 | 0.010 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2003 | 18 | 0.010 |
Why?
|
| Remission Induction | 1 | 2003 | 96 | 0.010 |
Why?
|
| Methotrexate | 1 | 2003 | 41 | 0.010 |
Why?
|
| Adult | 2 | 2008 | 8601 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 364 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2003 | 195 | 0.010 |
Why?
|
| Risk Factors | 1 | 2005 | 2443 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 1221 | 0.010 |
Why?
|
| Middle Aged | 1 | 2005 | 9823 | 0.010 |
Why?
|
| Female | 1 | 2005 | 16197 | 0.000 |
Why?
|